Augment
Ro vs TrumpRx
TL;DR: D2C telehealth platforms like Ro and Hims & Hers scaled from high-margin ED generics to even more lucrative GLP-1s, but Trump's TrumpRx platform now threatens to commoditize their obesity business. Sacra estimates that Ro hit $598M in annualized revenue in 2024, up 66% YoY from $360M in 2023. For more, check out our full report on Ro (dataset)...
First published on 12/20/2025
Log in to see this research
Augment
© Augment 2023 — All rights reserved. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, in addition to financial products and services through its wholly-owned but separately managed subsidiary, Augment Capital, LLC.
Securities products are offered through Augment Capital, LLC, member FINRA/ SIPC. Any information relating to fully diluted shares outstanding or other company related financing or capitalization information are estimates only and should be independently verified by each user in connection with any investment decision. Company data and portfolio calculations are provided by Augment for educational and illustrative purposes only. None of the information displayed on or downloadable from augment.market (the "Website") represents a recommendation, offer, solicitation of an offer, advice, or recommendation to buy, sell, or hold any security. All investing involves risk, including the risk of losing the money you invest, and past performance does not guarantee future performance.
Using the website or the information, tools, features or functionality provided on the website and by Augment Capital, LLC constitutes acceptance of the Augment terms of use, privacy policy, and other important disclosures. Review our Form CRS here.